2/26
11:26 am
acrs
Aclaris Therapeutics Highlights AD and Asthma Data Catalysts at Oppenheimer Healthcare Conference [Yahoo! Finance]
Low
Report
Aclaris Therapeutics Highlights AD and Asthma Data Catalysts at Oppenheimer Healthcare Conference [Yahoo! Finance]
2/26
07:32 am
acrs
Aclaris Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update [Yahoo! Finance]
Low
Report
Aclaris Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update [Yahoo! Finance]
2/26
06:58 am
acrs
Aclaris Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
Low
Report
Aclaris Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
2/24
07:00 am
acrs
Aclaris Therapeutics Initiates Phase 1b Proof-of-Concept Trial in Patients with Asthma with its Novel Bispecific Anti-TSLP/IL-4Ra Antibody ATI-052
Medium
Report
Aclaris Therapeutics Initiates Phase 1b Proof-of-Concept Trial in Patients with Asthma with its Novel Bispecific Anti-TSLP/IL-4Ra Antibody ATI-052
2/4
08:29 am
acrs
Aclaris Therapeutics to Participate in Two February Healthcare Conferences [Yahoo! Finance]
Low
Report
Aclaris Therapeutics to Participate in Two February Healthcare Conferences [Yahoo! Finance]
2/4
07:00 am
acrs
Aclaris Therapeutics to Participate in Two February Healthcare Conferences
Low
Report
Aclaris Therapeutics to Participate in Two February Healthcare Conferences
2/3
07:12 am
acrs
Aclaris Therapeutics (NASDAQ:ACRS) was upgraded by analysts at Craig Hallum to a "strong-buy" rating.
Low
Report
Aclaris Therapeutics (NASDAQ:ACRS) was upgraded by analysts at Craig Hallum to a "strong-buy" rating.
2/3
04:42 am
acrs
Biosion Announces First Patient Dosed in Investigator-Initiated Phase 1 Trial of BSI-082, a Next-Generation Anti-SIRPa Monoclonal Antibody for Advanced Solid Tumors [Yahoo! Finance]
Low
Report
Biosion Announces First Patient Dosed in Investigator-Initiated Phase 1 Trial of BSI-082, a Next-Generation Anti-SIRPa Monoclonal Antibody for Advanced Solid Tumors [Yahoo! Finance]
1/30
08:14 am
acrs
Aclaris Therapeutics (NASDAQ:ACRS) is now covered by analysts at Craig Hallum. They set a "buy" rating on the stock.
Low
Report
Aclaris Therapeutics (NASDAQ:ACRS) is now covered by analysts at Craig Hallum. They set a "buy" rating on the stock.
1/28
08:41 am
acrs
Aclaris Therapeutics (NASDAQ:ACRS) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $16.00 price target on the stock.
Medium
Report
Aclaris Therapeutics (NASDAQ:ACRS) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $16.00 price target on the stock.
1/27
07:07 am
acrs
Aclaris Therapeutics' Novel ITK/JAK3 Inhibitor ATI-2138 Demonstrates Rapid and Sustained Hair Regrowth in Validated Murine Model of Alopecia Areata (AA) [Yahoo! Finance]
Low
Report
Aclaris Therapeutics' Novel ITK/JAK3 Inhibitor ATI-2138 Demonstrates Rapid and Sustained Hair Regrowth in Validated Murine Model of Alopecia Areata (AA) [Yahoo! Finance]
1/27
06:55 am
acrs
Aclaris Therapeutics’ Novel ITK/JAK3 Inhibitor ATI-2138 Demonstrates Rapid and Sustained Hair Regrowth in Validated Murine Model of Alopecia Areata (AA)
Low
Report
Aclaris Therapeutics’ Novel ITK/JAK3 Inhibitor ATI-2138 Demonstrates Rapid and Sustained Hair Regrowth in Validated Murine Model of Alopecia Areata (AA)
1/21
08:00 am
acrs
Aclaris Therapeutics (NASDAQ:ACRS) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $16.00 price target on the stock.
Medium
Report
Aclaris Therapeutics (NASDAQ:ACRS) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $16.00 price target on the stock.
1/13
08:01 am
acrs
Aclaris Therapeutics initiates Phase 1b proof-of-concept trial of ATI-052 [Yahoo! Finance]
Low
Report
Aclaris Therapeutics initiates Phase 1b proof-of-concept trial of ATI-052 [Yahoo! Finance]
1/12
06:55 am
acrs
Aclaris Therapeutics Initiates Phase 1b Proof-of-Concept Trial in Atopic Dermatitis (AD) with Its Novel Bispecific Antibody ATI-052
Low
Report
Aclaris Therapeutics Initiates Phase 1b Proof-of-Concept Trial in Atopic Dermatitis (AD) with Its Novel Bispecific Antibody ATI-052
1/6
06:59 am
acrs
Aclaris Therapeutics Announces Positive Interim Results of Phase 1a Trial of Anti-TSLP/IL-4Ra Bispecific Antibody ATI-052 Supporting Expedited Clinical Development
Low
Report
Aclaris Therapeutics Announces Positive Interim Results of Phase 1a Trial of Anti-TSLP/IL-4Ra Bispecific Antibody ATI-052 Supporting Expedited Clinical Development
12/30
04:09 pm
acrs
Aclaris Therapeutics (NASDAQ:ACRS) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Medium
Report
Aclaris Therapeutics (NASDAQ:ACRS) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
12/23
04:09 pm
acrs
Aclaris Therapeutics (NASDAQ:ACRS) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Medium
Report
Aclaris Therapeutics (NASDAQ:ACRS) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
12/19
07:04 pm
acrs
Aclaris Therapeutics Added to the NASDAQ Biotechnology Index (NBI) [Yahoo! Finance]
Low
Report
Aclaris Therapeutics Added to the NASDAQ Biotechnology Index (NBI) [Yahoo! Finance]
12/19
04:01 pm
acrs
Aclaris Therapeutics Added to the NASDAQ Biotechnology Index (NBI)
Low
Report
Aclaris Therapeutics Added to the NASDAQ Biotechnology Index (NBI)